Hydrocodone: uses, dosing, side effects & brands
Hydrocodone is an opioid agonist sold in the U.S. under one brand, for cough, obstructive lung diseases and postoperative pain. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Opioid Agonist
- Treats
- Cough, Obstructive Lung Diseases and Postoperative Pain
- Available as
- Tablet, extended release
- Sold as
- Vantrela ER
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Half-life
- about 3.8 hours (3.8 ± 0.3 hours)
- What the pharmacy pays
- about $241 for a 30-count supply — not your price
- Boxed warning
- Boxed warning
How hydrocodone is dosed
From the FDA label for Vantrela ER (application NDA207975). Other hydrocodone products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Hydrocodone bitartrate extended-release tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks. ( 2.1 ) Daily doses of hydrocodone bitartrate extended-release tablets greater than or equal to 80 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established. ( 2.1 ) Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. ( 2.1 ) Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. ( 2.1 ) Reserve titration to higher doses of hydrocodone bitartrate extended-release tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. ( 2.1 , 5.1 ) Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse. ( 2.1 , 5.1 ) Respiratory…
Hydrocodone side effects
The following serious adverse reactions are described elsewhere in the labeling: Addiction, Abuse, and Misuse [see Warnings and Precautions ( 5.1 )] Life-Threatening Respiratory Depression [see Warnings and Precautions ( 5.2 )] Interactions with Benzodiazepine or Other CNS Depressants [see Warnings and Precautions ( 5.3 )] Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions ( 5.4 )] Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions ( 5.7 )] Adrenal Insufficiency [see Warnings and Precautions ( 5.9 )] Severe Hypotension [see Warnings and Precautions ( 5.10 )] Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.13 , 5.14 )] Seizures [see Warnings and Precautions ( 5.15 )] Withdrawal [see Warnings and Precautions ( 5.16 )] Most common treatment-emergent adverse events (incidence ≥ 5%) are constipation, nausea, vomiting, fatigue, upper respiratory tract infection, dizziness, headache, and somnolence. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alvogen, Inc. at 1-866-770-3024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A…
Who shouldn’t take hydrocodone
Hydrocodone bitartrate extended-release tablets are contraindicated in patients with: Significant respiratory depression [see Warnings and Precautions ( 5.2 )] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions ( 5.8 )] Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions ( 5.13 , 5.14 )] Hypersensitivity to hydrocodone or any component of hydrocodone bitartrate extended-release tablets. Significant respiratory depression ( 4 ) Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment ( 4 ) Known or suspected gastrointestinal obstruction, including paralytic ileus ( 4 ) Hypersensitivity to hydrocodone or to any other components of hydrocodone bitartrate extended-release tablets ( 4 )
Hydrocodone drug interactions
Table 3 includes clinically significant drug interactions with hydrocodone bitartrate extended-release tablets. Table 3: Clinically Significant Drug Interactions with Hydrocodone Bitartrate Extended-Release Tablets Inhibitors of CYP3A4 Clinical Impact: The concomitant use of hydrocodone bitartrate extended-release tablets and CYP3A4 inhibitors can increase the plasma concentration of hydrocodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of hydrocodone bitartrate extended-release tablets and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate extended-release tablets is achieved [see Warnings and Precautions ( 5.6 )] . After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the hydrocodone plasma concentration will decrease [see Clinical Pharmacology ( 12.3 )] , resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to hydrocodone. Intervention: If concomitant use is necessary, consider dosage reduction of hydrocodone bitartrate extended-release tablets until stable drug effects are achieved. Evaluate patients at frequent intervals for respiratory depression and sedation. If a CYP3A4 inhibitor is discontinued, consider increasing the hydrocodone bitartrate extended-release tablets dosage until stable drug effects are achieved. Assess for signs of opioid withdrawal. Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir). CYP3A4 Inducers Clinical Impact: The concomitant use of hydrocodone bitartrate extended-release tablets and CYP3A4 inducers can decrease the plasma concentration of hydrocodone [see Clinical Pharmacology ( 12.3 )] , resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to hydrocodone [see Warnings and Precautions ( 5.6 )] . After stopping a CYP3A4 inducer, as the effects of the inducer decline, the hydrocodone plasma concentration will increase [see Clinical Pharmacology ( 12.3 )] , which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. Intervention: If concomitant use is necessary, consider increasing the hydrocodone bitartrate extended-release tablet dosage until stable drug effects are achieved. Evaluate for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider hydrocodone bitartrate extended-release tablet dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation. Examples: Rifampin, carbamazepine, phenytoin Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death [see Warnings and Precautions ( 5.3 )] . Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.1 , 5.2 , 5.3 )] . Examples: Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol. Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. Intervention: If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue hydrocodone bitartrate extended-release tablets if serotonin syndrome is suspected. Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.3 )] . Intervention: The use of hydrocodone bitartrate extended-release tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. Examples: Phenelzine, tranylcypromine, linezolid Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of hydrocodone bitartrate extended-release tablets and/or precipitate withdrawal symptoms. Intervention: Avoid concomitant use. Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Muscle Relaxants Clinical Impact: Hydrocodone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Intervention: Because respiratory depression may be greater than otherwise expected, decrease the dosage of hydrocodone bitartrate extended-release tablets and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider recommending or prescribing an opioid overdose reversal agent [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.2 , 5.3 )] . Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Intervention: Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Intervention: Evaluate patients for signs of urinary retention or reduced gastric motility when hydrocodone bitartrate extended-release tablets are used concomitantly with anticholinergic drugs. Strong Laxatives Clinical Impact: Concomitant use of hydrocodone bitartrate extended-release tablets with strong laxatives that rapidly increase gastrointestinal motility, may decrease hydrocodone absorption and result in decreased hydrocodone plasma levels. Intervention: If hydrocodone bitartrate extended-release tablets are used in these patients, regularly evaluate for the development of adverse events as well as changing analgesic requirements. Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. Discontinue hydrocodone bitartrate extended-release tablets if serotonin syndrome is suspected. ( 7 ) Mixed Agonists/Antagonists and Partial Agonist Opioid Analgesics: Avoid use with hydrocodone bitartrate extended-release tablets because they may reduce analgesic effect of hydrocodone bitartrate extended-release tablets or precipitate withdrawal symptoms. ( 7 ) Monoamine Oxidase Inhibitors (MAOIs) : Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI. ( 7 )
Every hydrocodone product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Vantrela ER.
What hydrocodone pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| HYD;30 | 30 mg | yellow | round | — |
| HYD;40 | 40 mg | gray | round | — |
| HYD;60 | 60 mg | white | round | — |
| HYD;80 | 80 mg | pink | round | — |
| HYD;100 | 100 mg | blue | round | — |
| HYD;20 | 20 mg | green | round | — |
| A392 | 20 mg | white | round | — |
| A393 | 30 mg | brown | round | — |
| A394 | 40 mg | pink | round | — |
| A395 | 60 mg | blue | round | — |
| A396 | 80 mg | purple | round | — |
| A397 | 100 mg | green | round | — |
Combination products containing hydrocodone
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
Hydrocodone and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for hydrocodone: levels in milk, effects in breastfed infants, and the drugs it would consider insteadHydrocodone is an opioid narcotic. Benzhydrocodone is a hydrocodone prodrug that is rapidly converted into hydrocodone in the gastrointestinal tract. Maternal use of oral opioids during breastfeeding can cause infant drowsiness, which may progress to rare but severe central nervous system depression. Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. If hydrocodone is required by the mother of a newborn, it is not a reason to discontinue breastfeeding; however, once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of oral hydrocodone to 2 to 3 days at a maximum dosage of 30 mg daily with close infant monitoring. If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
National Institute of Child Health and Human Development, record revised December 15, 2025. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about hydrocodone
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 127,371 reports naming hydrocodone, and the FDA flagged 89% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- emotional distress13,348 reports
- ill-defined disorder6,261 reports
- anxiety5,484 reports
- drug withdrawal syndrome neonatal4,776 reports
- foetal exposure during pregnancy4,650 reports
- depression4,640 reports
- developmental delay3,295 reports
- nausea3,182 reports
Read these as a signal, not a rate. A report does not mean hydrocodone caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
How long hydrocodone stays in your system
The elimination half-life of hydrocodone is about 3.8 hours (3.8 ± 0.3 hours). Hydrocodone is converted by the liver (via CYP2D6) to an active metabolite, hydromorphone; this metabolic step is well established even though this particular label's pharmacokinetics section does not name hydromorphone. The 3.8-hour value comes from a small study (five adult male subjects); clearance and half-life can be prolonged in people with impaired liver or kidney function, in older adults, and can vary with CYP2D6 metabolizer status.
DailyMed — Hydrocodone Bitartrate and Acetaminophen (tablet), Clinical Pharmacology / Pharmacokinetics ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Can you drink alcohol on hydrocodone?
The label says avoid it
The label's Boxed Warning addresses alcohol directly: concomitant use of this opioid with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. The Drug Interactions and Drug Abuse sections repeat that because the effect is additive (both depress the CNS), combining hydrocodone with alcohol raises the risk of hypotension, respiratory depression, and fatal overdose. This is an additive CNS/respiratory-depression warning, not a disulfiram-type reaction.
Stopping hydrocodone: withdrawal & how to come off
FDA boxed warning — physical dependence
The label states that physical dependence develops with continued use and that abrupt discontinuation or a significant dose reduction produces withdrawal signs and symptoms. It directs that the drug not be abruptly discontinued in a physically dependent patient; instead the prescriber gradually tapers the dose using a patient-specific plan based on the dose taken, duration of treatment, and the patient's attributes, since rapid tapering can cause serious withdrawal symptoms, uncontrolled pain, and suicide. The Boxed Warning separately describes Neonatal Opioid Withdrawal Syndrome (NOWS): prolonged opioid use in a pregnant woman can cause a potentially life-threatening withdrawal syndrome in the newborn that must be recognized and treated by neonatology experts.
This describes what the label says about stopping — not a schedule to follow on your own. Any change to hydrocodoneis your prescriber’s decision; stopping some medicines abruptly is dangerous.
Hydrocodone Bitartrate and Acetaminophen Tablets — DailyMed FDA Label ↗Related guides
Related calculators
Frequently asked questions
What is hydrocodone?
Hydrocodone bitartrate extended-release tablets are supplied in 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg and 120 mg film-coated tablets for oral administration. The tablet strengths describe the amount of hydrocodone per tablet as the bitartrate salt. Hydrocodone bitartrate is an opioid agonist.
What kind of drug is hydrocodone?
The FDA classifies hydrocodone as an opioid agonist. Opioid agonists bind opioid receptors (mainly mu receptors) on nerves in the brain and spinal cord, dampening the release of pain-signaling chemicals so fewer pain messages reach the brain, which relieves moderate to severe pain. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you drink alcohol while taking hydrocodone?
The label's Boxed Warning addresses alcohol directly: concomitant use of this opioid with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. The Drug Interactions and Drug Abuse sections repeat that because the effect is additive (both depress the CNS), combining hydrocodone with alcohol raises the risk of hypotension, respiratory depression, and fatal overdose. This is an additive CNS/respiratory-depression warning, not a disulfiram-type reaction. This is what hydrocodone's FDA label says; alcohol advice depends on your dose and health, so confirm with your pharmacist.
What happens if you stop taking hydrocodone?
The label states that physical dependence develops with continued use and that abrupt discontinuation or a significant dose reduction produces withdrawal signs and symptoms. It directs that the drug not be abruptly discontinued in a physically dependent patient; instead the prescriber gradually tapers the dose using a patient-specific plan based on the dose taken, duration of treatment, and the patient's attributes, since rapid tapering can cause serious withdrawal symptoms, uncontrolled pain, and suicide. The Boxed Warning separately describes Neonatal Opioid Withdrawal Syndrome (NOWS): prolonged opioid use in a pregnant woman can cause a potentially life-threatening withdrawal syndrome in the newborn that must be recognized and treated by neonatology experts. Do not stop hydrocodone on your own — any change is a prescriber-managed decision.
How long does hydrocodone stay in your system?
The elimination half-life of hydrocodone is about 3.8 hours (3.8 ± 0.3 hours) — that is how long the body takes to clear half of a dose. Hydrocodone is converted by the liver (via CYP2D6) to an active metabolite, hydromorphone; this metabolic step is well established even though this particular label's pharmacokinetics section does not name hydromorphone. The 3.8-hour value comes from a small study (five adult male subjects); clearance and half-life can be prolonged in people with impaired liver or kidney function, in older adults, and can vary with CYP2D6 metabolizer status. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.
Can you take hydrocodone with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run hydrocodone against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does hydrocodone come in?
Across the brands we track, hydrocodone is currently marketed as tablet, extended release, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic hydrocodone?
We do not currently list a generic-labelled hydrocodone product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
What should I avoid while taking hydrocodone?
Alcohol: the FDA label says to avoid alcohol — see the alcohol section above for what it actually says. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.
How long does Vicodin/Norco (hydrocodone) stay in your system?
"In your system" means two different things. First is how long the drug is chemically active and clearing: hydrocodone's elimination half-life is about 3.8 to 4 hours for the immediate-release form found in Vicodin and Norco (FDA NORCO label reports 3.8 ± 0.3 hours; StatPearls reports approximately 4 hours). Because a drug is largely eliminated after roughly 4 to 5 half-lives, hydrocodone itself is mostly cleared from the bloodstream within about 16 to 24 hours in a person with normal liver and kidney function. Second is how long a drug test can still DETECT it or its metabolites (norhydrocodone, an inactive metabolite, and hydromorphone, an active one) — this is longer than the clearance time and varies by test type, from about a day in blood up to about 90 days in hair (that hair figure is a general hair-testing convention applied to opioids, not a hydrocodone-specific measured value, and is not addressed by the sources cited below). The ranges below are approximate; only a clinician or testing lab can interpret a specific result.
How long is Vicodin/Norco (hydrocodone) detectable in a urine drug test?
Urine is the most common test. In a controlled single-dose study (two 10 mg Norco tablets in healthy volunteers), hydrocodone was detectable in urine for about 25 to 26 hours (mean ~25.5 h in the study) — about a day — using a sensitive 50 ng/mL cutoff, and for under 5 hours at a higher 2000 ng/mL cutoff; the inactive metabolite norhydrocodone persisted somewhat longer but still under about 40 hours (SAMHSA/Flegel controlled-dose study). Detection windows run longer with repeated or high-dose use, and figures reported across general clinical references vary because labs use different cutoffs, assays, and study populations — sources genuinely differ, so treat any single number as approximate. The exact window depends on dose, how long and how often it was used, individual metabolism, hydration, and the specific assay's cutoff. An important, honest point: hydrocodone is a semi-synthetic opioid, and many older "opiate" immunoassay screens are calibrated to morphine and codeine and can under-detect or miss hydrocodone, so labs often confirm with a specific opioid panel or GC/MS or LC-MS/MS testing. Ranges are approximate; only a clinician or testing lab can interpret a specific result. This is not advice about how to alter a test result.
How long does Vicodin/Norco (hydrocodone) show up in blood, saliva, or hair?
By test type: blood — the shortest window, up to about 24 hours, consistent with the roughly 4-hour half-life and with the controlled study in which blood levels fell off over the first day (SAMHSA/Flegel); saliva (oral fluid) — roughly 12 to 48 hours, within the same controlled study's oral-fluid collection window, with the exact figure varying by cutoff; and hair — hair testing is not addressed by the three sources cited below, but the standard hair-test window applied to opioids generally is up to about 90 days (roughly 3 months), reflecting hair growth rather than active drug levels. That 90-day figure is a general hair-testing convention, not a measured hydrocodone-specific value. These are approximate ranges that shift with dose, frequency of use, and individual factors, and only a clinician or testing lab can interpret a specific result.
What affects how long Vicodin/Norco (hydrocodone) stays in your system?
Several factors change both clearance and detection time. Dose and frequency matter most: a single low dose clears faster than chronic or high-dose use, which can accumulate the drug and its metabolites. Metabolism varies with age, genetics, and especially liver and kidney function — hydrocodone is metabolized in the liver by the CYP3A4 enzyme (to inactive norhydrocodone) and CYP2D6 (to active hydromorphone) and eliminated mainly through the kidneys, so impaired organ function or interacting medications can lengthen the window. Body composition and hydration also play a role, as does the specific test used and its cutoff threshold — a more sensitive assay detects lower amounts for longer, which is why published windows vary between labs. Because of this variability, published windows are approximate ranges, not guarantees; only a clinician or testing lab can interpret an individual result.
Cite this page
- APA
- pharmaranks. (2026, July 24). Hydrocodone: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/hydrocodone
- MLA
- “Hydrocodone: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/hydrocodone.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for hydrocodone on DailyMed (NIH) ↗ — including its boxed warning in full.